All In Biotech

Drug Trial Radar · NCT05608291

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,564 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,564

Actual

Start

Jan 16, 2023

Primary completion

Jan 15, 2027

Study completion Apr 3, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life.

Conditions

  • Melanoma

Interventions

  • FianlimabDrug

    Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

  • CemiplimabDrug

    Cemiplimab will be administered by IV infusion Q 3 weeks

  • PembrolizumabDrug

    Pembrolizumab will be administered by IV infusion Q 3 weeks

  • PlaceboDrug

    Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse free survival (RSF)Time frame: Up to 5 Years

Locations

211 sites in 22 countries. Site status is shown where the registry gives one.

  • UC San Diego

    La Jolla, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • John Wayne Cancer Institute (JWCI)

    Santa Monica, California

  • The Melanoma And Skin Cancer Institute

    Englewood, Colorado

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • Orlando Health

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York

  • Columbia University

    New York, New York

  • University of Rochester

    Rochester, New York

  • Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Duke Cancer Institute, University Hospital

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Ohio State University James Comprehensive Cancer Center

    Columbus, Ohio

  • St Lukes University Health Network

    Easton, Pennsylvania

  • University Of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Tennessee Oncology - Centennial Clinic Location

    Nashville, Tennessee

  • Verdi Oncology

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • Intermountain Medical Center

    Murray, Utah

  • University of Virginia Medical Center

    Charlottesville, Virginia

  • DIABAID - Instituto de Asistencia Integral en Diabetes

    Caba, Argentina

  • Fundacion Centro de Investigaciones para la Transformacion (CENIT)

    Caba, Buenos Aires, Argentina

  • Centro de Investigacion Pergamino

    Pergamino, Buenos Aires, Argentina

  • Clinica Viedma S.A.

    Viedma, Río Negro Province, Argentina

  • Instituto de Oncologia de Rosario

    Rosario, Santa Fe Province, Argentina

  • Centro Medico San Roque

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Blacktown Cancer and Haematology Centre - Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Lismore Base Hospital

    Lismore, New South Wales, Australia

  • Liverpool Hospital - Cancer Therapy Centre

    Liverpool, New South Wales, Australia

  • Melanoma Institute of Australia

    Wollstonecraft, New South Wales, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Calvary North Adelaide Hospital

    North Adelaide, South Australia, Australia

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.